TEYXOS 172 3/17/09 11:13 AM Page 3 - μ. πιτσιλιδης α.ε.
TEYXOS 172 3/17/09 11:13 AM Page 3 - μ. πιτσιλιδης α.ε.
TEYXOS 172 3/17/09 11:13 AM Page 3 - μ. πιτσιλιδης α.ε.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>TEYXOS</strong> <strong><strong>17</strong>2</strong> 3/<strong>17</strong>/<strong>09</strong> <strong>11</strong>:14 <strong>AM</strong> <strong>Page</strong> 58<br />
Σ Υ Ν Τ Ο Μ Η Ε Ν Η Μ Ε Ρ Ω Σ Η<br />
Έν<strong>α</strong> <strong>μ</strong>όριο των<br />
<strong>α</strong>ρθρικών κυττάρων,<br />
η cadherin-<strong>11</strong>,<br />
λ<strong>α</strong><strong>μ</strong>βάν<strong>ε</strong>ι <strong>μ</strong>έρος στη<br />
δι<strong>α</strong>δικ<strong>α</strong>σί<strong>α</strong> δη<strong>μ</strong>ιουργί<strong>α</strong>ς<br />
της φλ<strong>ε</strong>γ<strong>μ</strong>ονής.<br />
58 / MEDICAL EXPRESS / TEYXOΣ <strong><strong>17</strong>2</strong> / ΜΑΡΤΙΟΣ 20<strong>09</strong><br />
χρησι<strong>μ</strong>οποιούν τ<strong>α</strong> σκι<strong>α</strong>γρ<strong>α</strong>φικά <strong>μ</strong>έσ<strong>α</strong> που<br />
π<strong>ε</strong>ριέχουν γ<strong>α</strong>δολίνιο <strong>μ</strong><strong>ε</strong> προσοχή σ<strong>ε</strong><br />
<strong>α</strong>σθ<strong>ε</strong>ν<strong>ε</strong>ίς που υποβάλλοντ<strong>α</strong>ι σ<strong>ε</strong> <strong>α</strong>ι<strong>μ</strong>οκάθ<strong>α</strong>ρση<br />
κ<strong>α</strong>ι ν<strong>α</strong> <strong>α</strong>ν<strong>α</strong>φέρουν κάθ<strong>ε</strong> πιθ<strong>α</strong>νή<br />
π<strong>ε</strong>ρίπτωση NFD.<br />
Βιβλιογρ<strong>α</strong>φί<strong>α</strong>: Centers for Disease<br />
Control and Prevention (GDC). Nephrogenic<br />
fibrosing dermopathy associated with<br />
exposure to gadolinium – containing<br />
contrast agents – St. Louis. Missouri<br />
2002 – 2006. MMWR Morb Mortal<br />
Wkly Rep 2007 Feb 23; 56: <strong>13</strong>7 – 41.<br />
Μορι<strong>α</strong>κός π<strong>α</strong>ράγοντ<strong>α</strong>ς της<br />
ρ<strong>ε</strong>υ<strong>μ</strong><strong>α</strong>το<strong>ε</strong>ιδούς <strong>α</strong>ρθρίτιδ<strong>α</strong>ς<br />
Η ρ<strong>ε</strong>υ<strong>μ</strong><strong>α</strong>το<strong>ε</strong>ιδής <strong>α</strong>ρθρίτιδ<strong>α</strong> (RA) χ<strong>α</strong>ρ<strong>α</strong>κτηρίζ<strong>ε</strong>τ<strong>α</strong>ι<br />
<strong>α</strong>πό φλ<strong>ε</strong>γ<strong>μ</strong>ονή κ<strong>α</strong>ι πολλ<strong>α</strong>πλ<strong>α</strong>σι<strong>α</strong>σ<strong>μ</strong>ό<br />
των <strong>α</strong>ρθρικών κυττάρων.<br />
Τ<strong>α</strong> φάρ<strong>μ</strong><strong>α</strong>κ<strong>α</strong> που στοχ<strong>ε</strong>ύουν στις προφλ<strong>ε</strong>γ<strong>μ</strong>ονώδ<strong>ε</strong>ις<br />
κυττ<strong>α</strong>ροκίν<strong>ε</strong>ς, όπως ο<br />
π<strong>α</strong>ράγοντ<strong>α</strong>ς νέκρωσης όγκου-<strong>α</strong> (TNF<strong>α</strong>),<br />
έχουν β<strong>ε</strong>λτιώσ<strong>ε</strong>ι την <strong>α</strong>ντι<strong>μ</strong><strong>ε</strong>τώπιση<br />
της RA, <strong>α</strong>λλά <strong>ε</strong>π<strong>ε</strong>ιδή δ<strong>ε</strong>ν δρουν πάντ<strong>α</strong>,<br />
χρ<strong>ε</strong>ιάζοντ<strong>α</strong>ι κ<strong>α</strong>ι άλλ<strong>ε</strong>ς θ<strong>ε</strong>ρ<strong>α</strong>π<strong>ε</strong>ί<strong>ε</strong>ς. Μι<strong>α</strong><br />
ο<strong>μ</strong>άδ<strong>α</strong> <strong>α</strong>πό την Ι<strong>α</strong>τρική Σχολή του Χάρβ<strong>α</strong>ρντ<br />
<strong>α</strong>νέφ<strong>ε</strong>ρ<strong>ε</strong> ότι έν<strong>α</strong> <strong>μ</strong>όριο συγκόλλησης<br />
στην <strong>ε</strong>πιφάν<strong>ε</strong>ι<strong>α</strong> των κυττάρων<br />
του <strong>α</strong>ρθρικού υ<strong>μ</strong>έν<strong>α</strong>, η cadherin-<strong>11</strong>,<br />
προκ<strong>α</strong>λ<strong>ε</strong>ί φλ<strong>ε</strong>γ<strong>μ</strong>ονή κ<strong>α</strong>ι πολλ<strong>α</strong>πλ<strong>α</strong>σι<strong>α</strong>σ<strong>μ</strong>ό<br />
των <strong>α</strong>ρθρικών κυττάρων.<br />
Η ο<strong>μ</strong>άδ<strong>α</strong> χορήγησ<strong>ε</strong> σ<strong>ε</strong> ποντίκι<strong>α</strong> που<br />
έπ<strong>α</strong>σχ<strong>α</strong>ν <strong>α</strong>πό <strong>μ</strong>ι<strong>α</strong> <strong>α</strong>σθέν<strong>ε</strong>ι<strong>α</strong> π<strong>α</strong>ρό<strong>μ</strong>οι<strong>α</strong><br />
<strong>μ</strong><strong>ε</strong> την RA <strong>ε</strong>ιδικά <strong>α</strong>ντισώ<strong>μ</strong><strong>α</strong>τ<strong>α</strong> κ<strong>α</strong>τά της<br />
cadherin-<strong>11</strong> κ<strong>α</strong>ι έν<strong>α</strong> άλλο φάρ<strong>μ</strong><strong>α</strong>κο που<br />
<strong>ε</strong>ξ<strong>α</strong>σθ<strong>ε</strong>ν<strong>ε</strong>ί τη δράση της cadherin-<strong>11</strong>.<br />
Α<strong>μ</strong>φότ<strong>ε</strong>ρ<strong>ε</strong>ς οι θ<strong>ε</strong>ρ<strong>α</strong>π<strong>ε</strong>ί<strong>ε</strong>ς οδήγησ<strong>α</strong>ν σ<strong>ε</strong><br />
ση<strong>μ</strong><strong>α</strong>ντικά <strong>μ</strong><strong>ε</strong>ιω<strong>μ</strong>ένη κ<strong>α</strong>τ<strong>α</strong>στροφή του<br />
<strong>α</strong>ρθρικού χόνδρου κ<strong>α</strong>ι (σ<strong>ε</strong> <strong>μ</strong>ικρότ<strong>ε</strong>ρο<br />
β<strong>α</strong>θ<strong>μ</strong>ό) των οστών. Δ<strong>ε</strong>ν ση<strong>μ</strong><strong>ε</strong>ιώθηκ<strong>ε</strong><br />
κ<strong>α</strong><strong>μ</strong>ί<strong>α</strong> <strong>α</strong>ν<strong>ε</strong>πιθύ<strong>μ</strong>ητη <strong>ε</strong>νέργ<strong>ε</strong>ι<strong>α</strong>.<br />
Σχόλιο: Στη ρ<strong>ε</strong>υ<strong>μ</strong><strong>α</strong>το<strong>ε</strong>ιδή <strong>α</strong>ρθρίτιδ<strong>α</strong>, τ<strong>α</strong><br />
κύττ<strong>α</strong>ρ<strong>α</strong> του <strong>α</strong>ρθρικού υ<strong>μ</strong>έν<strong>α</strong> θ<strong>ε</strong>ωρούντ<strong>α</strong>ν<br />
π<strong>α</strong>ρ<strong>α</strong>δοσι<strong>α</strong>κά ως ο <strong>α</strong>βοήθητος στόχος<br />
<strong>μ</strong>ι<strong>α</strong>ς <strong>α</strong>υτοάνοσης <strong>ε</strong>πίθ<strong>ε</strong>σης. Η έρ<strong>ε</strong>υν<strong>α</strong><br />
<strong>α</strong>υτή κ<strong>α</strong>τ<strong>α</strong>λήγ<strong>ε</strong>ι στο συ<strong>μ</strong>πέρ<strong>α</strong>σ<strong>μ</strong><strong>α</strong> ότι<br />
έν<strong>α</strong> <strong>μ</strong>όριο των <strong>α</strong>ρθρικών κυττάρων, η<br />
cadherin-<strong>11</strong>, λ<strong>α</strong><strong>μ</strong>βάν<strong>ε</strong>ι <strong>μ</strong>έρος στη δι<strong>α</strong>δικ<strong>α</strong>σί<strong>α</strong><br />
δη<strong>μ</strong>ιουργί<strong>α</strong>ς της φλ<strong>ε</strong>γ<strong>μ</strong>ονής. Αν<br />
κ<strong>α</strong>ι δ<strong>ε</strong>ν <strong>ε</strong>ίν<strong>α</strong>ι βέβ<strong>α</strong>ιο ότι τ<strong>α</strong> στοιχ<strong>ε</strong>ί<strong>α</strong> <strong>α</strong>υτά<br />
που βρέθηκ<strong>α</strong>ν σ<strong>ε</strong> ποντίκι<strong>α</strong> θ<strong>α</strong> <strong>μ</strong>πορέσουν<br />
ν<strong>α</strong> <strong>ε</strong>φ<strong>α</strong>ρ<strong>μ</strong>οστούν κ<strong>α</strong>ι στον άνθρωπο,<br />
υπάρχ<strong>ε</strong>ι <strong>μ</strong><strong>ε</strong>γάλη πιθ<strong>α</strong>νότητ<strong>α</strong> κάτι τέτοιο<br />
ν<strong>α</strong> ισχύ<strong>ε</strong>ι. Ήδη γίν<strong>ε</strong>τ<strong>α</strong>ι έρ<strong>ε</strong>υν<strong>α</strong> κ<strong>α</strong>ι γι<strong>α</strong><br />
άλλ<strong>α</strong> φάρ<strong>μ</strong><strong>α</strong>κ<strong>α</strong> που <strong>ε</strong>ξ<strong>α</strong>σθ<strong>ε</strong>νούν τη λ<strong>ε</strong>ιτουργί<strong>α</strong><br />
της cadherin-<strong>11</strong>. Αυτό το <strong>ε</strong>ντ<strong>ε</strong>λώς<br />
νέο <strong>ε</strong>ίδος θ<strong>ε</strong>ρ<strong>α</strong>π<strong>ε</strong>ί<strong>α</strong>ς, ίσως σ<strong>ε</strong> συνδυ<strong>α</strong>σ<strong>μ</strong>ό<br />
<strong>μ</strong><strong>ε</strong> φάρ<strong>μ</strong><strong>α</strong>κ<strong>α</strong> κ<strong>α</strong>τά του π<strong>α</strong>ράγοντ<strong>α</strong><br />
νέκρωσης όγκου (anti-TNF), <strong>ε</strong>ίν<strong>α</strong>ι πολύ<br />
πιθ<strong>α</strong>νό ν<strong>α</strong> βρ<strong>ε</strong>θ<strong>ε</strong>ί στο <strong>ε</strong>πίκ<strong>ε</strong>ντρο των κλινικών<br />
<strong>μ</strong><strong>ε</strong>λ<strong>ε</strong>τών των <strong>ε</strong>πό<strong>μ</strong><strong>ε</strong>νων <strong>ε</strong>τών.<br />
Βιβλιογρ<strong>α</strong>φί<strong>α</strong>: 1. Lee Dm et al.<br />
Cadherin <strong>11</strong> in synovial lining formation<br />
and pathology in arthritis. Science 2007<br />
Feb 16; 315: 1006 – 10.<br />
2. Firesterin GS. Every joint has a silver<br />
lining Science 2007 Feb 16; 315: 952<br />
– 3.<br />
Τόπος κ<strong>α</strong>τοικί<strong>α</strong>ς<br />
κ<strong>α</strong>ι πν<strong>ε</strong>υ<strong>μ</strong>ονική λ<strong>ε</strong>ιτουργί<strong>α</strong><br />
στ<strong>α</strong> π<strong>α</strong>ιδιά<br />
Τ<strong>α</strong> στοιχ<strong>ε</strong>ί<strong>α</strong> συγχρονικών <strong>μ</strong><strong>ε</strong>λ<strong>ε</strong>τών δ<strong>ε</strong>ίχνουν<br />
ότι η έκθ<strong>ε</strong>ση στην κυκλοφορι<strong>α</strong>κή<br />
κίνηση συσχ<strong>ε</strong>τίζ<strong>ε</strong>τ<strong>α</strong>ι <strong>μ</strong><strong>ε</strong> <strong>α</strong>ν<strong>ε</strong>πιθύ<strong>μ</strong>ητ<strong>α</strong><br />
<strong>α</strong>ποτ<strong>ε</strong>λέσ<strong>μ</strong><strong>α</strong>τ<strong>α</strong> στο <strong>α</strong>ν<strong>α</strong>πν<strong>ε</strong>υστικό<br />
σύστη<strong>μ</strong><strong>α</strong> των π<strong>α</strong>ιδιών. Σ<strong>ε</strong> <strong>α</strong>υτή τη <strong>μ</strong><strong>ε</strong>λέτη<br />
συ<strong>μ</strong><strong>μ</strong><strong>ε</strong>τ<strong>ε</strong>ίχ<strong>α</strong>ν 3677 π<strong>α</strong>ιδιά της Τ<strong>ε</strong>τάρτης<br />
τάξης του Δη<strong>μ</strong>οτικού, <strong>α</strong>πό 12 κοινότητ<strong>ε</strong>ς<br />
της δυτικής Κ<strong>α</strong>λιφόρνι<strong>α</strong> κ<strong>α</strong>ι οι<br />
<strong>ε</strong>ρ<strong>ε</strong>υνητές προσδιόρισ<strong>α</strong>ν σ<strong>ε</strong> πόση <strong>α</strong>πόστ<strong>α</strong>ση<br />
<strong>α</strong>πό το σπίτι κάθ<strong>ε</strong> π<strong>α</strong>ιδιού βρισκότ<strong>α</strong>ν<br />
έν<strong>α</strong>ς <strong>α</strong>υτοκινητόδρο<strong>μ</strong>ος τ<strong>α</strong>χ<strong>ε</strong>ί<strong>α</strong>ς<br />
κυκλοφορί<strong>α</strong>ς. Επί 8 έτη, κάθ<strong>ε</strong> π<strong>α</strong>ιδί<br />
υποβ<strong>α</strong>λλότ<strong>α</strong>ν σ<strong>ε</strong> <strong>ε</strong>τήσι<strong>α</strong> <strong>μ</strong><strong>ε</strong>λέτη της<br />
πν<strong>ε</strong>υ<strong>μ</strong>ονικής λ<strong>ε</strong>ιτουργί<strong>α</strong>ς του κ<strong>α</strong>ι η οικογέν<strong>ε</strong>ι<strong>α</strong><br />
κάθ<strong>ε</strong> <strong>μ</strong><strong>α</strong>θητή συ<strong>μ</strong>πλήρων<strong>ε</strong> έν<strong>α</strong><br />
<strong>ε</strong>τήσιο <strong>ε</strong>ρωτη<strong>μ</strong><strong>α</strong>τολόγιο γι<strong>α</strong> πιθ<strong>α</strong>νούς<br />
συγχυτικούς π<strong>α</strong>ράγοντ<strong>ε</strong>ς.<br />
Σ<strong>ε</strong> σύγκριση <strong>μ</strong><strong>ε</strong> τ<strong>α</strong> π<strong>α</strong>ιδιά που κ<strong>α</strong>τοικούσ<strong>α</strong>ν<br />
σ<strong>ε</strong> <strong>α</strong>πόστ<strong>α</strong>ση άνω των 1500<br />
<strong>μ</strong>έτρων <strong>α</strong>πό <strong>α</strong>υτοκινητόδρο<strong>μ</strong>ο τ<strong>α</strong>χ<strong>ε</strong>ί<strong>α</strong>ς<br />
κυκλοφορί<strong>α</strong>ς, <strong>ε</strong>κ<strong>ε</strong>ίν<strong>α</strong> που κ<strong>α</strong>τοικούσ<strong>α</strong>ν<br />
σ<strong>ε</strong> <strong>α</strong>πόστ<strong>α</strong>ση ως 500 <strong>μ</strong>έτρ<strong>α</strong> <strong>ε</strong>ίχ<strong>α</strong>ν σ<strong>ε</strong><br />
στ<strong>α</strong>τιστικά ση<strong>μ</strong><strong>α</strong>ντικό β<strong>α</strong>θ<strong>μ</strong>ό <strong>μ</strong><strong>ε</strong>ιω<strong>μ</strong>ένη<br />
<strong>α</strong>νάπτυξη του FEV1 κ<strong>α</strong>ι της <strong>μ</strong>έγιστης<br />
ροής στο <strong>μ</strong>έσο της <strong>ε</strong>κπνοής του FEV1,<br />
κ<strong>α</strong>τά τη διάρκ<strong>ε</strong>ι<strong>α</strong> των 8 <strong>ε</strong>τών π<strong>α</strong>ρ<strong>α</strong>κολούθησης.<br />
Η προσ<strong>α</strong>ρ<strong>μ</strong>ογή των δ<strong>ε</strong>δο<strong>μ</strong>ένων<br />
σύ<strong>μ</strong>φων<strong>α</strong> <strong>μ</strong><strong>ε</strong> την κοινωνικοοικονο<strong>μ</strong>ική<br />
κ<strong>α</strong>τάστ<strong>α</strong>ση <strong>ε</strong>νέτ<strong>ε</strong>ιν<strong>ε</strong> το συσχ<strong>ε</strong>τισ<strong>μ</strong>ό<br />
<strong>μ</strong><strong>ε</strong>τ<strong>α</strong>ξύ <strong>ε</strong>γγύτητ<strong>α</strong>ς στον <strong>α</strong>υτοκινητόδρο<strong>μ</strong>ο<br />
κ<strong>α</strong>ι <strong>μ</strong><strong>ε</strong>ιω<strong>μ</strong>ένης <strong>α</strong>νάπτυξης του FEV1.<br />
Π<strong>α</strong>ρ<strong>α</strong>τηρήθηκ<strong>α</strong>ν στ<strong>α</strong>τιστικά ση<strong>μ</strong><strong>α</strong>ντικές<br />
<strong>α</strong>ν<strong>ε</strong>πιθύ<strong>μ</strong>ητ<strong>ε</strong>ς <strong>ε</strong>πιδράσ<strong>ε</strong>ις της <strong>ε</strong>γγύτη-
Change language